HK1149011A1 - Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments - Google Patents

Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments

Info

Publication number
HK1149011A1
HK1149011A1 HK11103239.2A HK11103239A HK1149011A1 HK 1149011 A1 HK1149011 A1 HK 1149011A1 HK 11103239 A HK11103239 A HK 11103239A HK 1149011 A1 HK1149011 A1 HK 1149011A1
Authority
HK
Hong Kong
Prior art keywords
triazolopyridazines
production
producing medicaments
par1 inhibitors
par1
Prior art date
Application number
HK11103239.2A
Other languages
English (en)
Inventor
Uwe Heinelt
Volkmar Wehner
Matthias Herrmann
Karl Schoenafinger
Henning Steinhagen
Bodo Scheiper
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1149011A1 publication Critical patent/HK1149011A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11103239.2A 2008-02-05 2011-03-30 Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments HK1149011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290112 2008-02-05
PCT/EP2009/000406 WO2009097970A1 (de) 2008-02-05 2009-01-23 Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
HK1149011A1 true HK1149011A1 (en) 2011-09-23

Family

ID=39539711

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103239.2A HK1149011A1 (en) 2008-02-05 2011-03-30 Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments

Country Status (32)

Country Link
US (2) US8076336B2 (es)
EP (1) EP2240487B1 (es)
JP (1) JP5526040B2 (es)
KR (1) KR20100114514A (es)
CN (1) CN101981034B (es)
AR (1) AR070410A1 (es)
AT (1) ATE537172T1 (es)
AU (1) AU2009211887B2 (es)
BR (1) BRPI0907486A2 (es)
CA (1) CA2713550C (es)
CL (1) CL2009000236A1 (es)
CO (1) CO6260083A2 (es)
CY (1) CY1113228T1 (es)
DK (1) DK2240487T3 (es)
ES (1) ES2379447T3 (es)
HK (1) HK1149011A1 (es)
HR (1) HRP20120230T1 (es)
IL (1) IL207205A0 (es)
MA (1) MA32061B1 (es)
MX (1) MX2010008490A (es)
MY (1) MY152040A (es)
NZ (1) NZ587141A (es)
PA (1) PA8814801A1 (es)
PE (1) PE20091455A1 (es)
PL (1) PL2240487T3 (es)
PT (1) PT2240487E (es)
RS (1) RS52264B (es)
RU (1) RU2499797C2 (es)
SI (1) SI2240487T1 (es)
TW (1) TW200946532A (es)
WO (1) WO2009097970A1 (es)
ZA (1) ZA201004467B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066676A1 (en) * 2006-09-18 2009-06-10 Vertex Pharmaceuticals, Inc. HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
EP2240486B1 (de) * 2008-02-05 2015-09-09 Sanofi Triazoliumsalze als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
IL287901B1 (en) * 2019-06-19 2024-10-01 Nmd Pharma As Process for making CLC-1 chloride channel inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) * 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
AU695377B2 (en) * 1994-09-16 1998-08-13 Takeda Chemical Industries Ltd. Triazolopyridazines process and intermediates for their preparation and their use as medicaments
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
CN1243735C (zh) * 2001-04-19 2006-03-01 卫材株式会社 2-亚氨基吡咯烷衍生物
CA2448509A1 (en) 2001-05-25 2002-12-05 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having analgesic activity
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
US7037920B2 (en) 2001-10-18 2006-05-02 Schering Corporation Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
AR039570A1 (es) 2002-04-16 2005-02-23 Schering Corp Antagonistas de los receptores de trombina
EP2444393A1 (en) * 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
TW200531688A (en) * 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
EP1813282A4 (en) 2004-11-09 2011-03-02 Eisai R&D Man Co Ltd MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT
BRPI0620292B1 (pt) * 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
DE102006036023A1 (de) * 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
EP2240486B1 (de) * 2008-02-05 2015-09-09 Sanofi Triazoliumsalze als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
DK2242740T3 (da) * 2008-02-05 2013-03-25 Sanofi Sa SF5-derivater som par1-inhibitorer, deres fremstilling og anvendelse som lægemidler
KR20100121612A (ko) * 2008-02-05 2010-11-18 사노피-아벤티스 Par1 억제제로서의 이미다조피리다진, 이의 제조방법, 및 약제로서의 용도
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors

Also Published As

Publication number Publication date
ES2379447T3 (es) 2012-04-26
HRP20120230T1 (hr) 2012-04-30
CA2713550C (en) 2016-06-14
MA32061B1 (fr) 2011-02-01
JP2011511016A (ja) 2011-04-07
US9079906B2 (en) 2015-07-14
RU2499797C2 (ru) 2013-11-27
ZA201004467B (en) 2011-09-28
NZ587141A (en) 2012-04-27
EP2240487A1 (de) 2010-10-20
DK2240487T3 (da) 2012-04-02
RS52264B (en) 2012-10-31
CY1113228T1 (el) 2016-04-13
MX2010008490A (es) 2010-08-18
WO2009097970A1 (de) 2009-08-13
EP2240487B1 (de) 2011-12-14
PE20091455A1 (es) 2009-10-22
RU2010136957A (ru) 2012-03-20
KR20100114514A (ko) 2010-10-25
CL2009000236A1 (es) 2009-06-05
CA2713550A1 (en) 2009-08-13
CO6260083A2 (es) 2011-03-22
SI2240487T1 (sl) 2012-04-30
CN101981034B (zh) 2013-08-14
PT2240487E (pt) 2012-03-08
US20110034451A1 (en) 2011-02-10
PA8814801A1 (es) 2009-09-17
ATE537172T1 (de) 2011-12-15
BRPI0907486A2 (pt) 2015-07-14
IL207205A0 (en) 2010-12-30
AU2009211887A1 (en) 2009-08-13
PL2240487T3 (pl) 2012-05-31
AU2009211887B2 (en) 2013-09-19
US20120010203A1 (en) 2012-01-12
AR070410A1 (es) 2010-04-07
JP5526040B2 (ja) 2014-06-18
US8076336B2 (en) 2011-12-13
CN101981034A (zh) 2011-02-23
TW200946532A (en) 2009-11-16
MY152040A (en) 2014-08-15

Similar Documents

Publication Publication Date Title
IL245050A0 (en) Optimum fc variants, pharmaceutical preparations and drugs containing them, and a method for their preparation
IL211115A0 (en) Novel benzamides, production thereof, and use thereof as medicaments
PT2242740E (pt) Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL219530A (en) Converted 4-aminocyclohexane compounds, drugs containing these compounds and their use in the preparation of drugs
ZA200805939B (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EP2239054A4 (en) CATALYST, MANUFACTURING METHOD AND USE THEREOF
IL212605A (en) Pyrimidine-4-carboxamide cycles and their use as drugs
IL216826A0 (en) Pyridil-triazine derivatives, compositions comprising the same and processes for producing the same
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
HK1167597A1 (en) Dodeca-2e,4e-diene amides and their use as medicaments and cosmetics -2e4e-
IL210869A (en) Derivatives of imidaziadiazoles, their process, preparation, uses and medications containing them
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
IL211713A (en) History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
EP2239055A4 (en) CATALYST, MANUFACTURING METHOD AND USE THEREOF
IL215835A (en) Carboxamide compounds and their use as a drug
HK1149012A1 (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
HK1148956A1 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
HK1149011A1 (en) Triazolopyridazines as par1 inhibitors, production thereof, and use for producing medicaments
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
EP2330212A4 (en) NEW CERAMIDASTINE COMPOUND AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2363132A4 (en) USE OF SOPHORICOSIDE IN DRUG MANUFACTURE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180123